Major Histocompatibility Complex–Neoantigen Peptide–T-Cell Receptor Complex (MHC–Neoantigen–TCR Complex)

The MHC–neoantigen peptide–TCR complex is the fundamental structural unit of the adaptive immune system's recognition of malignant cells. It consists of a neoantigen—a mutant peptide derived from tumor-specific genomic alterations—bound within the groove of a Major Histocompatibility Complex (MHC) molecule and subsequently recognized by a specific T-cell receptor (TCR) [1][2]. Because neoantigens are derived from somatic mutations unique to the tumor, they are not present in healthy tissues, making this complex an ideal target for highly specific cancer immunotherapies with minimal off-target effects [3]. Therapeutic strategies targeting this complex include personalized neoantigen vaccines, which prime the immune system to recognize these unique markers, and adoptive cell therapies using TCR-engineered T-cells (TCR-T) designed to bind the complex with high affinity [1][4]. The successful formation and recognition of this tripartite complex are essential for the induction of a robust, durable anti-tumor immune response in modern precision oncology.

Other names

pMHC-TCR complexHLA-neoantigen-TCR complexNeoepitope-MHC-TCR complexAntigen-MHC-TCR tripartite complex

The complex acts as a molecular trigger for T-cell activation; therapeutic interventions either provide the neoantigen (vaccines) to stimulate endogenous TCR binding or provide engineered T-cells (TCR-T) that specifically dock with the MHC-peptide complex to induce tumor cell lysis via granzyme and perforin release [1][3].